Early detection of nephrotoxicity in patients with Medication-overuse headache (MOH)

Yzeiri Havziu, Drita and Gjorgjeska, Biljana and Cvetkovska, Dragana and Bilali, Sefedin and Nikolov, Igor (2019) Early detection of nephrotoxicity in patients with Medication-overuse headache (MOH). Acta Medica Balkanica International Journal of Medical Science, 4 (7-8). pp. 13-22. ISSN 2545-4870

[thumbnail of Acta Medica Balkanica Vol. 4  No. 7-8,  2019.pdf]
Preview
Text
Acta Medica Balkanica Vol. 4 No. 7-8, 2019.pdf

Download (12MB) | Preview

Abstract

Excessive drug use causes Medication-overuse headache (MOH) which can be manifested of chronic daily headaches, occurring monthly 15 or more days, when the medicament is used redundantly for more than three months. Recent studies concerning the epidemiology of drug-induced disorders suggest that increased risk of nephrotoxicity appears in a group of patients who abuse NSAIDs. The aim is to confirm the early phase of nephrotoxicity in patients with (MHO), divided in two groups: first group users of non-steroidal anti-inflammatory drugs (NSAIDs) and second group that use combinations of various analgesics, compared with 80 healthy individuals.
Besides conventional markers of renal functioning (serum/urine creatinine determined by Jaffe methods, enzymatic assay for urea serum and GFR by Cockcroft Gaunt formula), we will use colorimetric method determining N-acetyl–β-d-glucosaminidase–NAG, AlaninAminopeptidase-AAP in urine, IFCC for Gamma-glutamyltransferase- Y GT. Imunoturbodimetric assay for determination of urinary albumin, microalbuminuria and α1-microglobulin will be used.
After 12 months treatment of two groups of patients, no changes were found in the serum creatinine, serum urea and GFR, but extremely statistical difference (p <0.01) in the values of specific biomarkers, NAG, AAP, GGT, microalbuminuria in all patients, especially with combined therapie in the comparison with healthy patients.
We concluded changes on the glomerular and tubular level, despite the normal values of all the assayed conventional markers for renal function, We can’t confirm by nephrotoxicity, but if we follow the elevation of the level of the specific biomarkers, we will have an overview of the real state of functioning of the kidneys in patients with MHO.

Item Type: Article
Subjects: Medical and Health Sciences > Basic medicine
Medical and Health Sciences > Clinical medicine
Medical and Health Sciences > Health sciences
Divisions: Faculty of Medical Science
Depositing User: Biljana Gorgeska
Date Deposited: 18 Sep 2019 11:51
Last Modified: 18 Sep 2019 11:51
URI: https://eprints.ugd.edu.mk/id/eprint/22499

Actions (login required)

View Item View Item